Cargando…

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

The COVID-19 pandemic poses a global threat to public health and economy. The continuously emerging SARS-CoV-2 variants present a major challenge to the development of antiviral agents and vaccines. In this study, we identified that EK1 and cholesterol-coupled derivative of EK1, EK1C4, as pan-CoV fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Shuai, Lan, Qiaoshuai, Zhu, Yun, Wang, Chao, Xu, Wei, Li, Yutang, Wang, Lijue, Jiao, Fanke, Zhou, Jie, Hua, Chen, Wang, Qian, Cai, Xia, Wu, Yang, Gao, Jie, Liu, Huan, Sun, Ge, Münch, Jan, Kirchhoff, Frank, Yuan, Zhenghong, Xie, Youhua, Sun, Fei, Jiang, Shibo, Lu, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320318/ https://www.ncbi.nlm.nih.gov/pubmed/34326308 http://dx.doi.org/10.1038/s41392-021-00712-2

Ejemplares similares

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
por: Lan, Qiaoshuai, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
por: Xia, Shuai, et al.
Publicado: (2021)

25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

A core epitope targeting antibody of SARS-CoV-2
por: Zhao, Simeng, et al.
Publicado: (2022)

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
por: Xia, Shuai, et al.
Publicado: (2020)

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
por: Xia, Shuai, et al.
Publicado: (2020)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants
por: Pu, Jing, et al.
Publicado: (2022)

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
por: Cai, Yanxing, et al.
Publicado: (2020)

An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
por: Liu, Zezhong, et al.
Publicado: (2021)

A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
por: Cai, Yanxing, et al.
Publicado: (2021)

An inducible hACE2 transgenic mouse model recapitulates SARS-CoV-2 infection and pathogenesis in vivo
por: Liu, Kuo, et al.
Publicado: (2023)

Detection of SARS-CoV-2 in human breastmilk
por: Groß, Rüdiger, et al.
Publicado: (2020)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2
por: Gu, Chenjian, et al.
Publicado: (2021)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide
por: Li, Fei, et al.
Publicado: (2021)

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
por: Zhou, Yunjiao, et al.
Publicado: (2021)

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
por: Su, Shan, et al.
Publicado: (2022)

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies
por: Su, Xiaojie, et al.
Publicado: (2023)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
por: Ma, Cuiqing, et al.
Publicado: (2020)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Peptide and peptide-based inhibitors of SARS-CoV-2 entry
por: Schütz, Desiree, et al.
Publicado: (2020)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
por: Wang, Xinling, et al.
Publicado: (2023)

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant
por: Liu, Zezhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mjm2taoe8ac0a92rak7965a3c1